132 related articles for article (PubMed ID: 21270338)
1. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer.
Ito E; Yue S; Moriyama EH; Hui AB; Kim I; Shi W; Alajez NM; Bhogal N; Li G; Datti A; Schimmer AD; Wilson BC; Liu PP; Durocher D; Neel BG; O'Sullivan B; Cummings B; Bristow R; Wrana J; Liu FF
Sci Transl Med; 2011 Jan; 3(67):67ra7. PubMed ID: 21270338
[TBL] [Abstract][Full Text] [Related]
2. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer.
Ito E; Yip KW; Katz D; Fonseca SB; Hedley DW; Chow S; Xu GW; Wood TE; Bastianutto C; Schimmer AD; Kelley SO; Liu FF
Mol Pharmacol; 2009 Nov; 76(5):969-83. PubMed ID: 19654225
[TBL] [Abstract][Full Text] [Related]
3. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
4. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy.
Lin TY; Chang JT; Wang HM; Chan SH; Chiu CC; Lin CY; Fan KH; Liao CT; Chen IH; Liu TZ; Li HF; Cheng AJ
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):246-56. PubMed ID: 20615631
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
Vink SR; Lagerwerf S; Mesman E; Schellens JH; Begg AC; van Blitterswijk WJ; Verheij M
Clin Cancer Res; 2006 Mar; 12(5):1615-22. PubMed ID: 16533789
[TBL] [Abstract][Full Text] [Related]
6. Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer.
Ito E; Yip KW; Liu FF
Future Oncol; 2011 May; 7(5):595-7. PubMed ID: 21568673
[No Abstract] [Full Text] [Related]
7. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis.
Chen YJ; Chang JT; Lee L; Wang HM; Liao CT; Chiu CC; Chen PJ; Cheng AJ
Oncogene; 2007 Jan; 26(3):467-76. PubMed ID: 16878157
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.
Los G; Benbatoul K; Gately DP; Barton R; Christen R; Robbins KT; Vicario D; Kirmani S; Orloff LA; Weisman R; Howell SB
Clin Cancer Res; 1999 Jul; 5(7):1610-8. PubMed ID: 10430059
[TBL] [Abstract][Full Text] [Related]
10. Polymer chemotherapy for head and neck cancer.
Shikani AH; Domb AJ
Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
[TBL] [Abstract][Full Text] [Related]
11. A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors.
Tsou YA; Chen KC; Chang SS; Wen YR; Chen CY
J Biomol Struct Dyn; 2013 Dec; 31(12):1358-69. PubMed ID: 23140436
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201.
Huerta S; Gao X; Livingston EH; Kapur P; Sun H; Anthony T
Surgery; 2010 Aug; 148(2):346-53. PubMed ID: 20633731
[TBL] [Abstract][Full Text] [Related]
13. Taxol plus radiation for head and neck cancer.
Rosenthal DI; Carbone DP
J Infus Chemother; 1995; 5(2):46-54. PubMed ID: 8521234
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck.
Leonard CE; Chan DC; Chou TC; Kumar R; Bunn PA
Cancer Res; 1996 Nov; 56(22):5198-204. PubMed ID: 8912857
[TBL] [Abstract][Full Text] [Related]
16. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model.
Kim SY; Yang YS; Hong KH; Jang KY; Chung MJ; Lee DY; Lee JC; Yi HK; Nam SY; Hwang PH
Oral Oncol; 2008 Apr; 44(4):383-92. PubMed ID: 17690006
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
